Related Technologies - University of Pittsburgh

Search text

About 24 results

(0.08 seconds)

Compounds Targeting Androgen Receptor to Treat Castration-Resistant Prostate Cancer

02501

Castration-resistant prostate cancer (CRPC) is currently incurable and makes prostate cancer the second most common cause of cancer death among men in the United States.

Innovators at the University of Pittsburgh have identified novel small molecules that bind to the androgen receptor (AR) and block the nuclear localization and function of AR in CRPC cells.

Multiple studies have shown that the androgen receptor (AR) is activated via multiple mechanisms including AR overexpression, mutation, hypersensitization, and/or intratumoral androgen synthesis in patients relapsed after androgen deprivation therapy (ADT).

2011-06-10

Small Molecule Allosteric Modulators of Class B GPCRs in the PTHR and Method to Identify Them

05559

A structure-guided computational approach was used to identify allosteric druggable sites in PTHR and to predict compounds that would bind to this site, and Pitt researchers discovered four small-molecule compounds that act as negative allosteric modulators of PTHR signaling.

Parathyroid hormone (PTH) type 1 receptor (PTHR) is an indispensable G protein-coupled receptor (GPCR) of class B that functions to regulate blood levels of vitamin D, calcium, and phosphate ions in the body, as well as bone turnover.

A structure-guided computational approach was used to identify allosteric druggable sites in PTHR and to predict compounds that would bind to this site, and Pitt researchers discovered four small-molecule compounds that act as negative allosteric modulators of PTHR signaling.

Therapeutic Modality

Small Molecule

Musculoskeletal Endocrinology and Metabolic Diseases

Bioinformatics Small molecule

Ieva Sutkeviciute

Med-Pharmacology and Chemical Biology

2020-11-19

Novel Compounds to Inhibit TNF-Induced NF-κB Pathways

04864

B signaling pathway and responses of the same cell types to a library of bioactive compounds.

From the 717 initial hit compounds, docking studies were carried out in silico on key targets in the TNF receptor identifying three compounds of interest.

From the 717 initial hit compounds, docking studies were carried out in silico on key targets in the TNF receptor identifying three compounds of interest.

Med-Computational and Systems Biology

2019-01-22

A Novel Treatment for Metastatic Prostate Cancer